REFERENCES
- Lamm DL, Stodill B, Crispen R. Complications of Bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986; 135: 272–4.
- De Boisgisson PH, Roussel F, Leclerc D, Picquenot JM. Granulomatous renal mass during endovesical BCG therapy for bladder carcinoma: diagnosis by fine needle aspiration. Urology 1991; 37: 557–60.
- Katz DS, Wogalter H, D'Esp6sito RF, Cunha BA. Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 1992; 40: 63–6.
- Orihuela E, Herr HW, Pinsky CM, Whitemore WF. Toxicity for intravesical BCG and its management in patients with superficial bladder tumors. Cancer 1987; 60: 326–33.
- Stanisich TH, Brewer ML, Graham AR. Intravesical Bacillus Calmette-Guérin therapy and associated granu-lomatous renal masses. J Urol 1986; 135: 356–8.
- Deresiewics RL, Stone RM, Aster JC. Fatal dissemi-nated mycobacterial infection following intravesical Bacillus Calmette-Guérin. J Urol 1990; 144: 1331–4.
- Koukol SC, DeHaven JI, Riggs DR, Lamm DL. Drug therapy of Bacillus Calmette-Guérin sepsis. Urol Res 1995; 22: 373–6.
- Steg A, Lelen C, Debbre B, Bocco-Gibod L, Sicard D. Systemic Bacillus Calmette-Guérin Infection, "BCG-itis", in patients treated by intravesical bacillus therapy for bladder cancer. Eur Urol 1989; 16: 161–4.
- Rawls WH, Lamm DL, Lowe B, Crawford DE, Sarosdy MF, Montie JE, et al. Fatal sepsis following intravesical Bacillus Calmette-Guérin administration for bladder cancer. J Urol 1990; 144: 1328–30.
- Spimak JP, Lubke WL, Thompson IM, Lopez M. Dystrophic bladder wall calcifications following intra-vesical BCG. Treatment for superficial transitional cell carcinoma bladder. Urology 1993; 42: 89–92.
- Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827–33.